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Background: In 2006 WHO presented the infant and child growth charts suggested for universal application.
However, major determinants for perinatal outcomes and postnatal growth are laid down during antenatal
development. Accordingly, monitoring fetal growth in utero by ultrasonography is important both for clinical and
scientific reasons. The currently used fetal growth references are derived mainly from North American and
European population and may be inappropriate for international use, given possible variances in the growth rates
of fetuses from different ethnic population groups. WHO has, therefore, made it a high priority to establish charts of
optimal fetal growth that can be recommended worldwide.
Methods: This is a multi-national study for the development of fetal growth standards for international application
by assessing fetal growth in populations of different ethnic and geographic backgrounds. The study will select
pregnant women of high-middle socioeconomic status with no obvious environmental constraints on growth
(adequate nutritional status, non-smoking), and normal pregnancy history with no complications likely to affect fetal
growth. The study will be conducted in centres from ten developing and industrialized countries: Argentina, Brazil,
Democratic Republic of Congo, Denmark, Egypt, France, Germany, India, Norway, and Thailand. At each centre, 140
pregnant women will be recruited between 8 + 0 and 12 + 6 weeks of gestation. Subsequently, visits for fetal
biometry will be scheduled at 14, 18, 24, 28, 32, 36, and 40 weeks (+/− 1 week) to be performed by trained
ultrasonographers.
The main outcome of the proposed study will be the development of fetal growth standards (either global or
population specific) for international applications.
Discussion: The data from this study will be incorporated into obstetric practice and national health policies at
country level in coordination with the activities presently conducted by WHO to implement the use of the Child
Growth Standards.
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Of the estimated 4 million neonatal deaths each year,
more than 60% are associated with low-birth-weight due
to intrauterine growth restriction and/or preterm deliv-
ery [1]. Accurate prenatal assessment of fetal growth and
gestational age to timely identify and adequately manage
cases of growth restriction and/or preterm delivery
should be considered a public health priority, especially
in developing countries where 98% of the worldwide
neonatal deaths occur.
Before the advent of ultrasonography, fetal growth was
assessed by evaluating newborn weight as the end point of
the intrauterine growth process. However, cumulative evi-
dence indicated that this birth weight curve approach did
not accurately describe the fetal growth process for new-
borns born before 37 weeks of pregnancy, and low birth
weight babies born at term. In response to this evidence,
the prenatal assessment of fetal growth and gestational
age in utero by means of ultrasonography was adopted as
standard practice in prenatal care throughout the world.
The adequacy of fetal size is currently assessed by compar-
ing the measurements of fetal anatomical parameters at a
given gestational age captured through ultrasonography
with reference percentiles of fetal size derived from popu-
lations of fetuses whose growth was assumed to be nor-
mal. These same reference percentiles can be used to
estimate gestational age from observed fetal size. The most
commonly used reference charts of size by gestational age
were developed based on data from populations of fetuses
in the United States or Europe. Since 1981, concerns have
been raised that such charts might not be appropriate for
use in other ethnic groups which may experience different
patterns of fetal growth [2-4]. If fetal growth is dependent
upon ethnic heritage, the potential for misclassification of
fetal growth abnormalities through the wide-scale applica-
tion of existing growth reference charts should generate
concerns regarding diagnostic and management decisions
made on the basis of ultrasonographic fetal growth assess-
ments. Others counter argue that environmental factors
play a more critical role in fetal growth than ethnicity, and
that all fetuses should undergo comparable growth pat-
terns in the absence of environmental constraints to
growth [5]. The need to resolve this debate makes the
development of fetal growth standards for international
application both timely and a priority for improving
maternal, fetal and newborn heath care worldwide [6].
Reliable standards of fetal growth are important for
assessing the wellbeing of each maternal-infant dyad, de-
termining the health status of populations, and monitoring
progress in fetal and newborn health and development.
Accurate fetal growth assessment is also important for
maternal health. Fetal growth abnormalities are often as-
sociated with pregnancy complications such as hyperten-
sive disorders and may affect how specific pregnancies aremanaged (e.g. the decision to perform a caesarean sec-
tion). Thus, the results of this study will be beneficial for
maternal and fetal/newborn health, they will support ef-
forts to provide a continuum of care for mothers and their
infants, and will be relevant to country efforts to accelerate
progress to achieving Millennium Development Goals 1,
4, and 5.
The following sections briefly describe the work done
and recommendations issued by the World Health
Organization in the field of growth assessment that led
to the development of this proposal.
In 2006 WHO released the WHO Child Growth Stan-
dards. These curves were the result of the WHO Multi-
centre Growth Reference Study (MGRS) [7] which had
two characteristics that made the study unique in its
field: i) the prescriptive approach [8-10]; ii) the inter-
national representation.
The proposed study is an extension of the MGRS to fetal
life. It will be based on the same prescriptive approach for
sample selection, and will ensure international representa-
tion by including populations from five continents. The
main outcome of the study, fetal growth reference stan-
dards, will complement the MGRS by extending the WHO
Child Growth Reference Charts to the prenatal period.
In 2002, a meeting of experts on the life course and
health convened by the WHO Department of Non Com-
municable Diseases and Mental Health, Chronic Diseases
and Health Promotion, identified as a top research prior-
ity, the “improvement of measures of intra-uterine growth
retardation (alternative to low-birth-weight) which must
reflect newborn body composition and fetal exposures that
may not necessarily be expressed in birth size” [11].
Recent findings relating fetal femur length as assessed
in-utero by ultrasonography with blood pressure levels in
childhood confirm that measures of fetal growth alterna-
tive to birth weight provide important information which
may help clarify the potential associations between fetal
growth abnormalities and postnatal risk of disease [12].
In December 2002, the WHO Department of Nutrition
organized a meeting of experts to review current know-
ledge and the practical implications of the interpretation
of birth weight as a health outcome. Further research to
develop fetal growth standards was identified as urgent
by the group.
Finally, in 1995, the WHO Expert Committee on Phys-
ical Status published the results of a three year collabora-
tive effort involving more than 100 experts who reviewed
the currently available data on body size and composition
at the different stages of life and their interpretation in
terms of nutrient intake, activity level and risk of disease
[13,14]. As a follow up of these recommendations, WHO
implemented and conducted the MGRS. In addition,
the WHO Expert Committees also recommended the
development of fetal growth reference data suitable for
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to implement those recommendations as a logical exten-
sion of the MGRS.
Methods
Study design
This will be a multi-country observational study aiming
at developing fetal growth standards for international
application. This study will use an inclusive approach
when selecting participating centres so that diverse
ethnic population groups and diverse geographic settings
are adequately represented. The following centres have
been identified to participate in the study based on the
proficient use of ultrasonography:
 Argentina: Centro Rosarino de Estudios Perinatales,
Rosario
 Brazil: University of Campinas, Campinas
 Democratic Republic of Congo: University of
Kinshasa, Kinshasa
 Denmark: Copenhagen University Rigshospitalet,
Copenhagen
 Egypt: Assiut University, Assiut
 France: Hôpital Antoine Béclère, Paris
 Germany: University Medical Center, Hamburg
 India: All India Institute of Medical of Sciences,
New Delhi
 Norway: University of Bergen, Bergen
 Thailand: Khon Kaen University, Khon Kaen
Eligibility criteria
In terms of the selection of a study participant, the
protocol will follow a prescriptive approach. Participants
with no known health, environmental, and/or socio-
economic constraints on fetal growth will be invited to
participate in the study if:
 They belong to a high socio-economic status and a
high level of parental education, in order to ensure that
the curves reflect, as much as possible, the true growth
potential of fetuses, by limiting, as much as possible,
the influence of environmental factors. Specific cut off
points in family income and education have been
identified by the MGRS and will be translated into
socio-economic indicators specific to the countries
participating in the proposed study [9,10,15];
 They live at an altitude lower than 1,500 m;
 They live near the study area. This will ensure
compliance with the study, follow up for the study
duration, and for potential future follow-up studies
in infancy, childhood and eventually adulthood;
 They are 18 years old or more (as younger women
are still growing and their babies may be smaller at
birth) and ≤ 40 years; They have a BMI between 18–30;
 They have a singleton pregnancy;
 Their gestational age at entry is between 8 + 0 to
12 + 6 weeks based on LMP (confirmed by
ultrasonography, please see Dating by ultrasound for
a more detailed description);
 They have no history of health, environmental or
economic constraints likely to impede fetal growth;
no need for long-term medication (including fertility
treatment); not smoking currently or in the previous
6 months; no history of recurrent miscarriages; and
any baby previously delivered pre-term (<37 weeks)
or with a birth weight <2,500 g (at 37 w 5% of
boys and 10% of girls in low-risk pregnancies will
be ≤2,500 g);
 There is no evidence in the present pregnancy of
congenital disease or fetal anomaly. Participation in
the study will cease if a major fetal anomaly is
detected or serious illness develops leading to IUGR
(birth weight below the 10th percentile of the
recommended gender-specific birth weight for
gestational age reference curves [16]); however, all
mothers recruited will be followed-up until the end
of the study for the purposes of describing the whole
population.
Study procedure
Women in the first trimester (before 12 + 6 weeks gesta-
tion) attending antenatal care clinics providing ultrasono-
graphic examinations will be approached by members of
the study team and asked to participate. Women will be
fully informed about the study objectives and procedures.
Only women who sign a consent form will be enrolled
into the study.
Fetuses will be scanned in the first trimester for the es-
timation of gestational age and subsequently at monthly
intervals for fetal biometry [17].
All infants will receive an anthropometrical assessment
after delivery, including measurement of birth weight
[18]. All pregnant women in the study will be adminis-
tered a 24-hour dietary recall at entry into the study,
and at approximately 28 and 36 weeks gestation, to as-
sess maternal nutritional status and ensure that women
enrolled in the study have an adequate diet and that
nutrient intake is in accordance with current pregnancy
recommendations [18,19]. At each visit, the obstetric
history of participating women will be updated to collect
information related to pathological processes that may
affect fetal growth, and blood pressure and proteinuria
will be measured.
No additional procedures will be added to routine
antenatal care provided at the study centres, with the ex-
ception of 4–5 additional ultrasonographic examinations
and three repeat 24-dietary recalls.
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Gestational age will be confirmed by measuring the crown-
rump length (CRL) between 8 + 0 to 12 + 6 weeks based on
LMP. Gestational age (GA) by CRL should agree with GA
by LMP to within 7 days. If LMP and CRL agree, CRL
measurement will be used for dating. The average of three
measurements will be used. If GA by CRL and GA by
LMP differ by more than 7 days, the woman is not eligible
for the study.
To acquire the CRL measurements, the midline sa-
gittal section of the whole fetus will be visualized with
the fetus horizontal on the screen at 90 degrees to
the angle of insonation [20]. GA will be assessed by
using the reference charts published by Robinson and
Fleming [19].
Fetal biometry
The first visit (dating scan) will be between 8 + 0 and
12 + 6 weeks, and subsequent visits for fetal biometry
will be scheduled at approximately 4 weekly (+/−
1 week) intervals at 14, 18, 24, 28, 32, 36, and
40 weeks. All scanning appointments will be arranged
at the time of the dating scan and study enrolment.
All participants will be scanned in the lateral recum-
bent position.
The compulsory ultrasound measurements to be ob-
tained at all visits include the following biometrical
parameters:
 Biparietal diameter (BPD)
 Head circumference (HC)
 Abdominal circumference (AC)
 Femur length (FL)
 Transcerebellar diameter (TCD)
 Humerus length (HL)
 Fetal Foot length (FFL)
At each examination, all measurements are to be
obtained three times from three separately generated
ultrasound images and uploaded electronically (with the
associated images) to the data management system. The
mean of the three measurements of each parameter will
be used for clinical management purposes as per local
protocols.
In addition, a full morphological evaluation (abnormal-
ity scan) will be conducted at 18–24 weeks following
standard practices at each centre. Fetuses diagnosed with
any minor abnormalities will be managed according to
local clinical guidelines. If the clinical decision is to
continue with the pregnancy the case will remain in the
study. Fetuses with major abnormalities that may affect
morphometric measurements will be excluded from fur-
ther study. All infants will receive an anthropometrical
assessment after delivery [21].The following measurement techniques will be used:
 Biparietal Diameter-Technique: Measured from the
outer-outer (BPD 1) and outer – inner (BPD 2) edges
of the parietal bones in a cross-sectional view of the
fetal head at the level of the thalami and cavum
septum pellucidum or cerebral peduncles. The
cerebellum is not to be included. The measurement
should be obtained from an image with the midline
echo as close as possible to the horizontal plane with
the angle of insonation of the ultrasound beam at
90 degrees.
 Head Circumference -Technique: Obtained from the
same image as BPD as follows: Measurement of
occipito-frontal diameter (OFD) obtained by placing
calipers on the outer borders of the occipital and
frontal edges of the skull at the point of the midline
across the longest part of the skull. The ellipse
facility will be used to calculate HC as above.
 Abdominal Circumference - Technique: The
sonographer will visualize the transverse section of
the fetal abdomen as “close as possible” to circular
including the stomach and the junction of the
umbilical vein and portal sinus. The anterior-
posterior (A-P) and transverse diameters will be
measured with calipers placed on the outer borders
of the body outline. The A-P diameter will be
measured from the spine to the anterior abdominal
wall and transverse diameter at a right angle to the
A-P diameter. The ellipse facility will be used to
calculate AC as outlined above.
 FL-Technique: Measured from an image of the full
femoral shaft in a plane as close as possible to a
right angle to the ultrasound beam. The distal
femoral epiphysis is to be excluded.
 Transcerebellar Diameter (TCD): the TCD can be
imaged from the sub-occipito-bregmatic view of the
fetal skull, and measured from the second trimester
onwards. The calipers will be placed on the
outer-outer margins of the cerebellar poles.
 Humerus length (HL): Measured from an image of
the full humeral shaft in a plane as close as possible
to a right angle of insonation.
 Fetal Foot Length (FFL): Fetal foot length will be
measured from the second trimester onwards. The
foot is measured from either sagittal or plantar views.
The measurement is taken from the skin overlying the
heel (calcaneus) to the end of the longest toe.
Ultrasound volume acquisition protocol
The ultrasonographic equipment that will be used in the
study will allow for acquiring and storing 3-dimensional
images. This feature is of critical importance for data
quality purposes. Stored 3-dimensional images (volumes)
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that have been identified as erroneous.
Except for a transvaginal scan during the first research
visit (8 0/7 -12 6/7 weeks), 3D volume data will other-
wise be acquired using a transabdominal probe. All vol-
umes shall be systematically labelled using the comment
feature of the Voluson E8 (GE Healthcare, Germany)
Expert system (e.g. “LA1”).
Recommended Image settings:
 At least High Quality 2
 CRI no greater than 2
 No speckle reduction (SRI)
 Harmonic imaging as needed
 Acoustic focus adjusted for the anatomic region
 Use the widest image window to capture the volume
of interest, depending on fetal activity
 Adjust the magnification and image depth settings
to fill at least one-half of the screen
Training
As done in previous studies [3,22] sonographers partici-
pating in the study will receive specific training and will
be certified as proficient under the supervision of a
qualified instructor, according to a standard protocol.
Intra-observer and inter-observer measurement errors
will be assessed according to a published protocol before
the initiation of the study during the training period
[21]. We will consider estimating a learning course [23].
All instruments and techniques to be used in all cen-
tres will be standardised, i.e. equipment and training will
be provided to each of the measurement teams. Equip-
ment specifications to be considered are the following: i)
Commercially available high quality real-time ultrasound
scanner; ii) Less than 2 years old; iii) T/V and abdominal
probes suitable for scanning throughout pregnancy;
iv) Facility for on-line transfer of measurements and
associated images; v) Facility to “blind” measurements
from examiner until after data transfer.
Site visits to the study centres will be organized in order
to provide lectures and update courses by experts in the
field. In addition during site visits, standardization sessions
will be carried out according to repeat-measure protocols
to assess the accuracy and precision of the anthropometri-
cal measurements in mothers and newborns.
Neonatal anthropometrical assessment
Neonatal body composition assessment during the first
24 hours will be used to determine the growth outcome of
each pregnancy on the basis of multiple postnatal mea-
surements in order to be able to relate pre- and postnatal
anthropometrical measurements. After delivery, a trained
investigator will take standardized measurements of the
head circumference, abdominal circumference (superiorborder of umbilicus), and thigh circumference (at the skin
crease located midway between the knee and trunk with
the lower leg at about 90 degrees in relation to the thigh
measured in centimetres) with non-stretchable tape. The
crown-heel length will be obtained by placing the supine
infant, with extended legs, on a plastic newborn length
board (Statiometer, Ellard Instrumentation, Seattle, WA,
USA). Skin fold caliper measurements (Harpenden) will
be used to document soft tissue distribution [17,24]. These
skin folds will include the triceps fold, anterior thigh fold,
sub-scapular skin fold, and abdominal flank skin fold that
will be made at each site twice and averaged. This data will
be used to estimate per cent body fat and lean body mass
as an index of neonatal growth outcome. Other parame-
ters of neonatal body composition will include ponderal
index and birth weight [25].
Nutritional assessment
Adequate nutrition is one of the major requirements for
selecting populations eligible for the study. Therefore,
the assessment and maintenance of adequate nutritional
status is considered a critical component of the study
activities.
At three times during the study follow-up (at entry and
at approximately 28 and 36 weeks) the nurse/nutritionist,
trained in collecting anthropometric and diet data, will as-
sess maternal nutritional status via anthropometry (weight,
height, arm circumference, head circumference, skinfolds)
(Table 1), as well as assessing the dietary intake (by twenty-
four-hour recall). Measurements will be carried out by a
female nurse/nutritionist in a private room according to
the procedures described by Gibson [17]. The time of the
examination will be recorded to allow for diurnal varia-
tions. Having only one person performing the measure-
ments will minimize inter-examiner errors. The equipment
required is already available at the study site.
Dietary intakes will be assessed using 24-hour recalls;
specifically a trained nutritionist or nurse will query the
study participants on foods and beverages consumed by
them in the previous 24-hours. Information will also
be collected on portion sizes as well as preparation
methods. This information will then be linked with
appropriate country-specific food composition tables to
arrive at estimates of macro and micro-nutrients [27,28].
This method results in the attainment of estimates of
the intake of single nutrients. Compliance is high be-
cause the respondent burden is low. The interview takes
approximately twenty minutes. The quality of the in-
formation collected is dependent on the respondent’s
motivation and ability to recall intakes and on the inter-
viewing skills of the nutritionist/nurse. Repeated twenty-
four-hour recalls on the same individual allow estimations
of the individual’s usual dietary intake over a long period
of time [28]. In our study the twenty-four-hour recall will
Table 1 Description of maternal anthropometric measures
Measure Procedure
Weight Weight will be measured using a beam balance with nondetachable weights. Weight will be recorded to the nearest
0.1 kg [26].
Height Height will be measured in the standing position using a stadiometer and recorded to the nearest millimetre. If the
reading falls between two values, the lowest millimetre will be recorded [26].
Mid-upper arm
circumference
Measurements will be taken using a flexible fiberglass tape wrapped around the upper left arm, at the midpoint between
the acromion process and the tip of the olecranon. Measurements will be recorded to the nearest millimetre [26].
Head circumference A flexible fiberglass tape will be used. The tape will be placed above the supra-orbital ridges and over the part of the
occiput which gives the maximum circumference. Measurements will be taken to the nearest millimetre [26].
Skinfolds Left triceps and left scapular skinfolds will be taken using a Lange skinfold thickness caliper. The combination of one body
and one limb skinfold to assess body fat is recommended by most investigators [26].
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been successfully used in previous studies focusing on
nutrition, fetal growth and other pregnancy outcomes
conducted by investigators who are taking part in the pro-
posed study.
Safety of ultrasonographic assessment
Ultrasonography in pregnancy is considered a safe
procedure and in more than 30 years no fetal harm has
been reported with use in the low-intensity range of
gray-scale imaging (no Doppler), which is the technology
that will be used in the proposed study [29]. Serial ultra-
sonography for research purposes according to schedules
similar to the one we propose has been approved previ-
ously in the context of other studies [30-33].
Following a recommendation of the WHO Scientific
and Ethical Review Group, we conducted a systematic
review and meta-analysis to evaluate the safety of human
intrauterine exposure to ultrasonography [32].
We systematically searched electronic databases, refer-
ence lists and unpublished literature according to the
following criteria:
 Types of studies: Trials and observational studies
that assessed short and long term effects of exposure
to ultrasonography during pregnancy.
 Types of participants: Women submitted to
ultrasonography in pregnancy and their offspring.
 Types of exposure: B-mode or Doppler sonography
during any period of pregnancy, for any number of
times, using any equipment and transducers.
 Types of outcome measures: 1) adverse maternal
outcomes, 2) adverse perinatal outcomes,
3) abnormal childhood neurological development,
and 4) childhood malignancies.
The electronic search identified 6716 citations and 63
were selected for full text evaluation. Additionally, 19
citations were identified from secondary sources. A total
of 58 references reporting data of 38 different studieswere included: 16 clinical trials, 11 cohorts, and 11 case
controls. Ultrasonography in pregnancy was not associ-
ated with adverse maternal effects, impaired physical or
neurological development or increased risk for malig-
nancies in childhood. According to the clinical trials,
there was a weak association between exposure to ultra-
sonography and non-right handedness in boys (OR 1.26,
95% CI 1.03-1.54) and a slight decrease in mean neonatal
length (WMD −0.26 cm, CI −0.45, −0.07) and head circum-
ference (WMD −0.15 cm, CI-0.29, −0.01). In conclusion,
based on the available evidence, exposure to diagnostic
ultrasonography during pregnancy appears to be safe.
Sample size
The total sample size will be 1400 pregnant women and
their infants. Each country centre will collect data from
140 women. This number is sufficient for the develop-
ment of local centile growth charts with a high level of
precision, accounting for exclusions to final analysis due
to inability to follow up and occurrence of pregnancy
complications [34,35].
The sample size needed for the estimation of a specific
percentile was computed using the following formula [36]:
n ¼ 1þ z
2
α=2
 
%SE Pα
%CV
 2
where zα is the standard normal deviation corresponding
to the percentile being estimated, % SE Cα is the ex-
pected percentage standard error of the percentile and %
CV is the percentage coefficient of variation. Sample
sizes were computed for 5 different parameters (biparie-
tal diameter, abdominal and head circumference and
femur and humerus length) and for 3 different percen-
tiles: 5%, 10% and 50%. Information about the coefficient
of variation was obtained from data on serial ultrasono-
graphic examination conducted on approximately 500
pregnancies in the context of the WHO randomized trial
of calcium supplementation in low intake women [37].
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interval with a sample size n = 100 was computed.
Table 2 shows the levels of precision obtainable with a
sample size of 100 women for various biometrical pa-
rameters. In addition the proposed sample size of 140
women per centre will allow for testing for differences in
growth patterns across centres [38].
The following table lists, for every biometrical param-
eter, the number of subjects needed to detect as statisti-
cally significant the smallest meaningful difference d with
type I error rate of 0.05 and a power of 0.80 with values ofTable 2 Levels of precision obtained with a sample size of 10
and half widths in mm)
Abdominal circ
Week Mean 10% Centile 5% Centile CV %SE_50
20 147.7 133.5 128.8 7.9 0.79
24 190.7 173.8 166.6 7.4 0.74
28 235.2 215.4 210.6 6.4 0.64
32 278.6 255.8 248.3 6.5 0.65
36 314.5 288.0 277.9 7.1 0.71
Biparietal d
Week Mean 10% Centile 5% Centile CV %SE_50
20 46.7 44.0 42.0 5.6 0.56
24 59.0 56.0 55.0 4.8 0.48
28 70.8 68.0 67.0 3.9 0.39
32 80.1 77.0 75.0 3.7 0.37
36 87.1 83.0 81.0 3.7 0.37
Head circum
Week Mean 10% Centile 5% Centile CV %SE_50
20 177.4 164.4 161.2 5.8 0.58
24 225.0 212.3 209.2 4.9 0.49
28 269.4 254.9 251.8 4.3 0.43
32 302.8 286.9 281.6 4.1 0.41
36 325.1 308.1 300.1 4.1 0.41
Femur le
Week Mean 10% Centile 5% Centile CV %SE_50
20 32.6 30.0 29.0 6.9 0.69
24 43.2 41.0 40.0 4.7 0.47
28 53.0 51.0 50.0 3.7 0.37
32 61.9 59.0 58.0 3.3 0.33
36 69.3 67.0 65.0 3.2 0.32
Humerus
Week Mean 10% Centile 5% Centile CV %SE_50
20 31.4 28.0 27.0 8.9 0.89
24 40.7 38.0 37.0 6.8 0.68
28 48.6 45.0 44.0 6.3 0.63
32 55.7 52.0 51.0 5.7 0.57
36 61.2 57.0 56.0 5.4 0.54variance (σ2) and correlation (ρ2) as estimated using the
data from the WHO randomized trial of calcium supple-
mentation in low intake women [37]. The presented sam-
ple sizes have been calculated by applying the formula:
m ¼ 2 zα þ zQ
 2
σ2 1−ρð Þ
ns2xd
2
Where d is the minimum difference in the rate of
change per unit time (week) in the five biometrical param-
eters by centre, n is the number of visits (n = 8) and s2x is0 women for some biometrical fetal parameters (values
umference
%SE_10 %SE_5 Width_50 Width_10 Width_5
1.07 1.21 2.33 2.85 3.12
1.00 1.14 2.82 3.47 3.78
0.86 0.98 3.01 3.72 4.13
0.88 1.00 3.62 4.49 4.95
0.96 1.09 4.47 5.52 6.05
iameter
%SE_10 %SE_5 Width_50 Width_10 Width_5
0.76 0.86 0.52 0.67 0.72
0.65 0.74 0.57 0.73 0.81
0.53 0.60 0.55 0.72 0.80
0.50 0.57 0.59 0.77 0.85
0.50 0.57 0.64 0.83 0.92
ference
%SE_10 %SE_5 Width_50 Width_10 Width_5
0.78 0.89 2.06 2.57 2.87
0.66 0.75 2.21 2.81 3.14
0.58 0.66 2.32 2.96 3.32
0.55 0.63 2.48 3.17 3.54
0.55 0.63 2.67 3.41 3.77
ngth
%SE_10 %SE_5 Width_50 Width_10 Width_5
0.93 1.06 0.45 0.56 0.61
0.63 0.72 0.41 0.52 0.58
0.50 0.57 0.39 0.51 0.57
0.45 0.51 0.41 0.53 0.59
0.43 0.49 0.44 0.58 0.64
length
%SE_10 %SE_5 Width_50 Width_10 Width_5
1.20 1.37 0.56 0.67 0.74
0.92 1.04 0.55 0.70 0.77
0.85 0.97 0.61 0.77 0.85
0.77 0.87 0.63 0.80 0.89
0.73 0.83 0.66 0.83 0.93
Merialdi et al. BMC Pregnancy and Childbirth 2014, 14:157 Page 8 of 9
http://www.biomedcentral.com/1471-2393/14/157the within subject variance [38]. The values of d shown in
Table 3 indicate that the sample size needed for the level
of precision requested will be very conservative to detect
differences in the rate of change between centres.
Data management
Data will be collected via an internet based data man-
agement system as done with other WHO coordinated
studies. The online data collection system will allow for
real time solutions of queries or other problems in data
collection, such as missing or non-valid data as well
as for online checking of images by the international
coordination unit.
All data will be stored in a GCP compliant server, and
data transmission will be encrypted to assure data integ-
rity and patient confidentiality. Access to the data man-
agement web system will be password protected and
only authorized users will have access. Data changes will
be documented. The system will maintain an audit trail,
data trail and edit trail as well as back up of the data.
Data entered into the web system will be checked by
the coordinating unit at WHO for completeness, accur-
acy, reliability and consistent intended performance. The
data management team will be responsible for generat-
ing the interim and final data report.
These procedures have been used in previous HRP
multi-centre trials and proven to be efficient and com-
pliant with the HRP/WHO Standard Operating Proce-
dures as well as with the 21 CFR Part 11 of the Code of
Federal Regulations that deals with the United States
Food and Drug Administration (FDA) guidelines on
electronic records.
Data analysis
Population percentiles will be calculated by applying
polynomial regression methods, using the generalized
estimating equations method, to model the mean at spe-
cific gestational ages, taking into account correlations
between repeated measurements on the same subjects
[38]. To estimate the standard deviations at each gesta-
tional age, we will use the method of the absolute resid-
uals proposed by Altman [39]. This methodology takes
into account the increase in variance with advancing
gestation typical of fetal biometry data [39]. DifferencesTable 3 Estimated sample size and computation
assumptions for biometrical parameters
Biometrical parameter Sample size Variance Rho d (mm)
Biparietal Diameter 32 10.2 0.34 0.1
Head circumference 23 174 0.28 0.5
Abdominal circumference 28 263 0.43 0.5
Femur length 16 5 0.32 0.1
Humerus length 35 11 0.32 0.1in linear growth among populations of different geo-
graphical origin (categorized by study site) will be tested
by evaluating the proportion of total variability in fetal
biometrical measurements attributable to sites and indi-
viduals, as well as differences among sites and the effect
of excluding sites on the percentiles of the total sample,
as done in the MGRS [40]. The same procedure will be
used to test for differences in growth related to the sex
of the fetus.
Discussion
The data from this study, if findings are similar across
diverse populations, may facilitate the adoption of an
universal growth standard for international use. If het-
erogeneity by centre is detected despite selecting study
populations according to the prescriptive approach, the
study results will indicate the need to develop local/
ethnically specific standards.
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